Neurogene (NGNE)
NASDAQ:NGNE
Want to see NGNE full AI Analyst Report?
Top Page
Neurogene
(NASDAQ:NGNE)
Select Model
Select Model
Rating:56Neutral
Price Target:
$29.00
▲(4.13% Upside)
Action:ReiteratedDate:04/21/26
The score is held back primarily by weak financial performance—minimal revenue alongside accelerating losses and cash burn—despite a low-debt balance sheet. Technicals are supportive with strong trend momentum but show overbought signals. Positive corporate events (Breakthrough designation and commercialization-focused leadership buildout) provide meaningful upside support, while valuation is difficult to anchor due to negative earnings and no dividend.
Positive Factors
Regulatory Progress
Breakthrough designation materially shortens development and review timelines and signals regulatory acknowledgement of clinical benefit. This structurally raises the probability of approval, improves attractiveness to partners, and de-risks the lead program beyond short-term market moves, aiding long-term commercialization planning.
Negative Factors
High Cash Burn
Sustained, large negative operating and free cash flow is a persistent structural constraint: it steadily depletes reserves and forces external financing. Until commercial revenues emerge or a major partnership is secured, this rising burn profile increases dilution risk and can limit strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
Breakthrough designation materially shortens development and review timelines and signals regulatory acknowledgement of clinical benefit. This structurally raises the probability of approval, improves attractiveness to partners, and de-risks the lead program beyond short-term market moves, aiding long-term commercialization planning.
Read all positive factors
Neurogene (NGNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$422.09M
Dividend YieldN/A
Average Volume (3M)225.72K
Price to Earnings (P/E)―
Beta (1Y)2.88
Revenue Growth-100.00%
EPS Growth-2.44%
CountryUS
Employees107
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.12
Shares Outstanding15,615,786
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-415.92
Enterprise Value/Ebitda-3.64
Forecast
1Y Price Target
$86.50Price Target Upside210.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.21
Revenue Forecast (FY)N/A
Neurogene Business Overview & Revenue Model
Company Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101...
How the Company Makes Money
Neurogene does not have publicly disclosed recurring commercial product revenue, and as a clinical-stage biotech it primarily funds operations through capital raises (e.g., issuing equity in public or private financings) and, when applicable, non-...
Neurogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 925.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.19M | -2.32M | -3.26M | -3.20M | -42.26M |
| EBITDA | -103.33M | -71.89M | -52.29M | -51.99M | -49.59M |
| Net Income | -90.35M | -75.14M | -36.32M | -55.19M | -50.52M |
Balance Sheet | |||||
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M |
| Cash, Cash Equivalents and Short-Term Investments | 269.01M | 312.40M | 197.16M | 82.02M | 70.54M |
| Total Debt | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M |
| Total Liabilities | 23.72M | 25.36M | 36.55M | 10.64M | 193.36M |
| Stockholders Equity | 264.89M | 310.38M | 186.02M | 98.63M | -91.88M |
Cash Flow | |||||
| Free Cash Flow | -78.36M | -71.41M | -51.74M | -55.05M | -64.77M |
| Operating Cash Flow | -77.17M | -70.60M | -51.42M | -52.82M | -46.40M |
| Investing Cash Flow | 14.00M | -125.26M | 25.64M | -2.23M | -18.37M |
| Financing Cash Flow | 30.43M | 184.07M | 92.48M | 66.53M | 51.06M |
Neurogene Technical Analysis
Positive
27.85
Price Trends
20.48
Positive
19.97
Positive
21.53
Positive
Market Momentum
1.06
Negative
70.54
Negative
90.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Positive. The current price of 27.85 is above the 20-day moving average (MA) of 21.36, above the 50-day MA of 20.48, and above the 200-day MA of 21.53, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 70.54 is Negative, neither overbought nor oversold. The STOCH value of 90.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NGNE.
Neurogene Risk Analysis
Neurogene disclosed 86 risk factors in its most recent earnings report. Neurogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neurogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $435.81M | -1.84 | -46.34% | ― | ― | 2.37% | |
56 Neutral | $422.09M | -4.83 | -32.99% | ― | -100.00% | -2.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $215.05M | -3.95 | -977.67% | ― | ― | 42.43% | |
49 Neutral | $363.70M | -6.10 | -300.94% | ― | ― | ― | |
47 Neutral | $674.58M | -0.19 | 72.70% | ― | ― | -880.05% | |
44 Neutral | $145.87M | -1.20 | -85.20% | ― | ― | 52.32% |
* Healthcare Sector Average
NGNE
Neurogene
27.05
12.55
86.55%
SLN
Silence Therapeutics
7.82
4.32
123.43%
AVIR
Atea Pharmaceuticals
5.36
2.40
81.08%
ELTX
Elicio Therapeutics
11.36
6.39
128.57%
VOR
Vor Biopharma
14.12
0.17
1.22%
TNYA
Tenaya Therapeutics
0.70
0.22
44.93%
Neurogene Corporate Events
Business Operations and StrategyExecutive/Board Changes
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization
Positive
Apr 20, 2026
On April 20, 2026, Neurogene’s board expanded to seven members and appointed President and Chief Financial Officer Christine Mikail as a Class II director with a term through the 2028 annual meeting. The move formalizes Mikail’s influe...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy
Positive
Feb 26, 2026
On February 26, 2026, Neurogene announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, its late-stage investigational AAV9 gene therapy for Rett syndrome. The decision was based on interim Phase 1...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.